Gainers

• QTREX Quantum (NASDAQ:QTEX) stock moved upwards by 13.8% to $2.64 during Tuesday's after-market session. The market value of their outstanding shares is at $134.2 million.
• Connect Biopharma Hldgs (NASDAQ:CNTB) stock rose 13.48% to $2.44. The market value of their outstanding shares is at $147.3 million.
• PharmaCyte Biotech (NASDAQ:PMCB) stock moved upwards by 8.32% to $0.81. The market value of their outstanding shares is at $8.5 million.
• Biodexa Pharmaceuticals (NASDAQ:BDRX) stock moved upwards by 7.71% to $3.77. The market value of their outstanding shares is at $2.4 million.
• NeuroSense Therapeutics (NASDAQ:NRSN) stock increased by 7.46% to $0.86. The company's market cap stands at $29.3 million.
• ALPS Group (NASDAQ:ALPS) stock moved upwards by 6.63% to $0.74. The market value of their outstanding shares is at $121.4 million.

Losers

• NRX Pharmaceuticals (NASDAQ:NRXP) stock fell 19.1% to $3.74 during Tuesday's after-market session. The company's market cap stands at $167.3 million.
• BNB Plus (NASDAQ:BNBX) stock declined by 9.89% to $0.49. The company's market cap stands at $3.9 million.
• China Pharma Holding (AMEX:CPHI) stock declined by 7.8% to $0.79. The company's market cap stands at $31.1 million.
• Indaptus Therapeutics (NASDAQ:INDP) stock decreased by 7.33% to $1.99. The company's market cap stands at $217.4 million.
• Genenta Science (NASDAQ:GNTA) shares declined by 6.37% to $2.06. The company's market cap stands at $38.6 million.
• Aktis Oncology (NASDAQ:AKTS) shares fell 6.22% to $19.0. The company's market cap stands at $1.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.